Bioventus to Acquire Misonix, Enhance Surgical Solutions

Bioventus and Misonix entered into a definitive agreement by which Bioventus will acquire Misonix for $518 million in a cash-and-stock transaction that is expected to close in 4Q21.

Following close, the combined company will conduct business as Bioventus Inc. and will leverage the global strengths of both product brands as a pure-play...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us